Clinical trial
A Study of TAS-120 in Patients With Advanced Solid Tumors
NCT02052778 · Taiho Oncology, Inc., Industry · Completed
Key facts
| NCT number | NCT02052778 |
|---|---|
| Title | A Study of TAS-120 in Patients With Advanced Solid Tumors |
| Official title | Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations |
| Lead sponsor | Taiho Oncology, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | Futibatinib |
| Enrollment | 407 |
| Start date | Jul 21, 2014 |
| Primary completion | Oct 1, 2020 |
| Completion | Oct 22, 2024 |
| First posted | Feb 3, 2014 |
| Last update posted | Mar 27, 2025 |
| Countries | Australia, Canada, France, Germany, Hong Kong, Italy, Japan, Netherlands, South Korea, Spain, Taiwan, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: